MaxCyte Inc - cell-engineering technology platform based in US state of Maryland - Non-Executive Chair Richard Douglas buys 80,000 shares at average USD4.32, worth USD345,480, on Wednesday. Now has. | March 30, 2023
MaxCyte Inc on Tuesday said it appointed Douglas Swirsky as its new chief financial officer, effective immediately.
The Maryland, US-based cell-engineering focused company said Swirsky previously. | March 28, 2023
ROCKVILLE, Md., March 27, 2023 MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization. | March 27, 2023